TUT-7 early Phase II clinical study for various solid tumors and hematologic malignancies

T. Taguchi, A. Wakui, H. Niitani, H. Furue, H. Majima, K. Ota, H. Ariyoshi, T. Hattori, K. Tsukagoshi, K. Sugimachi, S. Tsukagoshi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An early Phase II study with TUT- 7 (menogaril), a new anthracycline antitumor antibiotic, was conducted in patients with various malignant tumors at 81 departments of 65 institutions nationwide. One course of TUT-7 treatment consisted of seven (7) or fourteen (14 consecutive days of administration at 75 or 100 mg/body/day with two-week drug withdrawal; at least two courses of treatment were given in principle. Among the 165 patients registered, 145 patients were eligible and 128 patients were evaluable for antitumor efficacy. In 11 patients with malignant lymphoma, one (1) had CR and five (5) had PR (54.5%); in three (3) patients with prostate cancer, one (1) had PR (33.3%); and in 12 patients with uterine cervical cancer, two (2) had PR (16.7%). Adverse drug reactions frequently observed were digestive organ disorders (anorexia and nausea/vomiting) and malaise. The abnormality in laboratory tests observed frequently was myelosuppression (leukopenia and neutropenia).

Original languageEnglish
Pages (from-to)1253-1261
Number of pages9
JournalJapanese Journal of Cancer and Chemotherapy
Volume24
Issue number10
Publication statusPublished - 1997

Keywords

  • Early phase II clinical study
  • Menogaril

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'TUT-7 early Phase II clinical study for various solid tumors and hematologic malignancies'. Together they form a unique fingerprint.

  • Cite this

    Taguchi, T., Wakui, A., Niitani, H., Furue, H., Majima, H., Ota, K., Ariyoshi, H., Hattori, T., Tsukagoshi, K., Sugimachi, K., & Tsukagoshi, S. (1997). TUT-7 early Phase II clinical study for various solid tumors and hematologic malignancies. Japanese Journal of Cancer and Chemotherapy, 24(10), 1253-1261.